Published in:
01-08-2021 | Bariatric Surgery | Letter to the Editor
Two cases of euglycemic diabetic ketoacidosis after bariatric surgery associated with sodium-glucose cotransporter-2 inhibitor use
Authors:
Erica A. Amianda, Thomas S. Gavigan, Toghrul Talishinskiy, Douglas R. Ewing, Hans J. Schmidt
Published in:
Obesity Surgery
|
Issue 8/2021
Login to get access
Excerpt
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were FDA approved in 2013 as an adjunct to glucophage for type 2 diabetes mellitus (T2DM). They are commonly utilized in patients with obesity because they also lower blood pressure, have weight loss benefits and cardiovascular disease benefits. Euglycemic diabetic ketoacidosis (EDKA) is a known adverse effect of this medication, and decreased intake after bariatric surgery (BS) increases that risk. We describe two cases of patients who stopped their SGLT2i as instructed prior to BS and developed severe EDKA requiring hospitalization. …